Appropriate Use Criteria
- R. Parker Ward, MD
What are appropriate use criteria?
For the explanation of appropriate use criteria (AUC), please see Chapter 65 .
What led to the development of appropriate use criteria?
AUC were developed in response to the marked increase in the performance of and expenditures on cardiac procedures, particularly cardiac imaging, over the past two decades. Medical diagnostic imaging experienced a cumulative growth of 85% between 2000 and 2009, including a near doubling in the volume of transthoracic echocardiography (TTE). , This exceeded the growth of any other physician service. , Although an aging population with an increasing burden of cardiovascular disease may justify some of this growth, the magnitude of this increase in utilization and expenditures raised questions from governmental and private payers about potential misuse and overuse of cardiac imaging procedures. ,
As a result of this increased scrutiny, more recent utilization of cardiac imaging procedures, including echocardiography, has moderated. Between 2009 and 2011, the most recent time frame for which data are available, for the first time volume of all imaging services to Medicare beneficiaries declined (3.5%). Utilization of echocardiography procedures has been a similar path, declining 5.5% over the same time period ( Fig. 198.1 ).
Although the reasons for the reduction in utilization of echocardiography have not been definitively determined, contributors have been identified. Reimbursement cuts that took effect in January 2010 and implementation of utilization management efforts such as prior authorization processes have been examples of successful governmental and private-payer attempts to decrease utilization and contain costs. , The development of AUC has also played an important role, representing a physician directed effort to provide practitioners and reimbursement agencies “a rational approach to the use of diagnostic imaging in the delivery of high quality care.” To this end, the AUC have raised physician awareness and provided a vehicle to guide the optimal use of echocardiography in current clinical practice.
What do the appropriate use criteria for echocardiography tell us about current clinical practice?
Since publication of the AUC for echocardiography, a large of number of clinical implementation studies have provided a description of the appropriateness of the current clinical practice of echocardiography in a variety of populations and practice settings. The following themes have emerged.
A large majority of echocardiography procedures performed are appropriate. For TTE, depending on population and practice setting, 71% to 92% of studies have been found to be ordered for “appropriate” indications. The most common appropriate indications for which TTE are ordered in clinical practice are listed in Box 198.1 . For transesophageal echocardiography (TEE), an even greater percentage of studies are ordered for “appropriate” indications (95%), likely because the invasive nature of TEE requires greater physician involvement and screening. , The AUC for stress echocardiography (SE) are discussed in another chapter in this book.
Indication 1: Symptoms or conditions potentially related to a cardiac etiology, including but not limited to chest pain, shortness of breath, palpitations, TIA, stroke, or peripheral embolic event (AUC score = 9)
Indication 2: Prior testing that is concerning for heart disease or structural abnormality, including but not limited to chest X-ray, baseline scout images for stress echocardiogram, ECG, or cardiac biomarkers (AUC score = 9)
Indication 5: Sustained or nonsustained atrial fibrillation, SVT, or VT (AUC score = 9)
Indication 9: Syncope when there are no other signs of cardiovascular disease (AUC score = 7)
Indication 34: Initial evaluation when there is a reasonable suspicion of valvular heart disease (AUC score = 9)
Indication 58: Suspected cardiovascular sours of embolus (AUC score = 9)
Indication 71: Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam without a clear precipitating change in medication or diet (AUC score = 8)
Indication 73: Re-evaluation of known HF (systolic or diastolic) to guide therapy (AUC score = 9)
AUC, Appropriate use criteria; ECG, electrocardiogram; HF, heart failure; SVT, supraventricular tachycardia; TIA, transient ischemic attack; VT, ventricular tachycardia.
A wide range of rates of “inappropriate” (now termed “rarely appropriate”) TTE studies have been reported (2% to 22%), whereas “rarely appropriate” TEEs (3% to 4%) have been shown to be extremely rare. , The most common “rarely appropriate” indications for which TTEs are ordered in clinical practice are listed in Box 198.2 . “Rarely appropriate” echocardiographic studies have been the primary target of efforts to reduce utilization of echocardiographic procedures. Educational interventions aimed at orienting ordering clinicians to the AUC have been shown to be successful in reducing the number of inappropriate TTEs performed.
Indication 8: Lightheadedness/presyncope when there are no other symptoms or signs of cardiovascular disease (AUC score = 3)
Indication 11: Routine surveillance of ventricular function with known CAD and no change in clinical status or cardiac examination (AUC score = 3)
Indication 13: Routine preoperative evaluation of ventricular function with no symptoms or signs of cardiovascular disease (AUC score = 2)
Indication 38: Routine surveillance (< 3 year) of mild valvular stenosis without a change in clinical status or cardiac examination (AUC score = 3)
Indication 48: Routine surveillance (< 3 years after valve implantation) of prosthetic valve if no known or suspected valve dysfunction (AUC score = 3)
Indication 53: Suspected endocarditis in a patient with transient fever without evidence of bacteremia or new murmur (AUC score = 2)
Indication 68: Routine evaluation of systemic hypertension without symptoms or signs of heart disease (AUC score = 3)
Indication 74: Routine surveillance (< 1 year) of heart failure (systolic or diastolic) when there is no change in clinical status or cardiac examination (AUC score = 2)
AUC, Appropriate use criteria; CAD, coronary artery disease.
What can we learn from “inappropriate” (now termed “rarely appropriate”) studies?
There has been great interest in identifying characteristics of “rarely appropriate” studies that might be used to target efforts to reduce inappropriate utilization of echocardiography, constrain costs, and optimize clinical practice. Characteristics such as practice setting (community vs. academic) have not been shown to significantly affect appropriateness. , Physician ordering specialty (cardiologist vs. other) has been studied extensively, with mixed effects on the appropriateness of echo practice in different populations studied. , , The two characteristics that have consistently been associated with more “rarely appropriate” TTEs are outpatient status and repeat studies. Outpatient TTEs are less appropriate than inpatient TTEs in large part because hospitalized patients are more likely to have new symptoms or a “change in clinical status,” which the key feature establishing many AUC indications as “appropriate.” , , Similarly, repeat TTEs are less likely to be appropriate than first-time TTEs because indications in the AUC specify time intervals for reevaluation of heart disease in the absence of a clinical change; below these intervals, the repeat TTE would not be deemed appropriate (e.g., AUC indication 35: “Routine surveillance (< 3 years) of mild valvular heart disease without a change in clinical status or cardiac exam”). , Routine repeat TTEs are among the most common “rarely appropriate” indications for TTE in clinical practice and represent a primary target to optimize utilization.
How will the appropriate use criteria be implemented into clinical practice?
AUC were developed with the expectation that they will be implemented in the routine clinical practice of echocardiography. Over the past decade, cardiac imaging tests have increasingly been subjected to precertification or prior-authorization procedures before performance of individual imaging procedures. , These precertification procedures are generally performed by radiology benefit managers (RBMs) on behalf of third-party payers. , Although successful in limiting utilization, these processes have been unwieldy for physicians and patients as they may delay or deny necessary imaging tests. , The AUC have been put forth as an alternative to prior authorization. Electronic applications and software to be incorporated as part of order entry in electronic medical record systems have been developed and found to be feasible to employ in clinical practice. , Currently, the AUC for a variety of cardiac imaging modalities are being piloted as a potential replacement for, or to facilitate, prior authorization procedures in a number of locations across the country.
AUC reporting is also now a requirement for imaging laboratory accreditation for all cardiac imaging modalities, including echocardiography. The Intersocietal Commission for Accreditation of Echocardiography Laboratories (ICAEL) currently requires that the AUC be applied to 30 consecutive TTEs, TEEs, and SEs annually, with laboratory appropriateness rates included in annual quality improvement documentation. In addition, laboratories must have a “mechanism for educating referring physicians to improve appropriate use.”
Carotid Ultrasound to Evaluate Cardiovascular Disease Risk: Carotid Intima-Media Thickness and Plaque Detection
- James H. Stein, MD
- Claudia E. Korcarz, DVM, RDCS
Atherosclerosis typically causes cardiovascular disease (CVD) when it progresses to a flow-limiting obstruction that causes ischemia, or when a severe obstruction suddenly develops as a result of rupture or erosion of a preexisting plaque with subsequent thrombosis. Although not all individuals with atherosclerotic plaque will experience a CVD event, a greater degree of subclinical atherosclerosis is predictive of increased risk for future CVD events. To prevent the complications of CVD such as death, myocardial infarction, and stroke, there is great interest in identifying asymptomatic patients who would be candidates for more intensive, evidence-based medical interventions that reduce CVD risk. Imaging of arteries to identify and quantify the presence of subclinical vascular disease has been suggested to further refine CVD risk assessment. B-mode ultrasound measurement of carotid intima-media thickness (IMT) in conjunction with screening for carotid plaque presence is a noninvasive, sensitive, and reproducible approach for identifying and quantifying atherosclerotic burden and CVD risk. For CVD risk assessment, ultrasound is used to characterize the carotid artery wall, rather than luminal narrowing, to identify early stages of arterial injury and atherosclerosis. Ultrasound imaging of the far wall of the carotid artery produces two echogenic lines, the lumen-intima and the media-adventitia interface, which together constitute the IMT. The most recent guidelines from the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) for assessment of CVD risk in asymptomatic adults designated ultrasound carotid IMT with a Class IIa recommendation (level of evidence B) for CVD risk assessment in patients at intermediate risk. The ACCF/AHA guideline also recommended careful adherence to published recommendations from the American Society of Echocardiography (ASE) regarding ultrasound instrumentation, technical approach to imaging, and operator training and experience “to achieve high-quality results.” No imaging tests were designated as a level I recommendation by the ACCF/AHA. A Current Procedural Terminology code (0126 T) has been established by the United States Centers for Medicare and Medicaid for “Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment.”
Many individuals are classified as being low CVD risk despite having increased lifetime risk of CVD. In a seminal report from two large epidemiological studies, young and middle-aged adults (≤ 50 years of age) with low 10-year risk of coronary heart disease but a high predicted lifetime risk had high carotid IMT. Scores of studies have demonstrated a strong relationship between future CVD risk and increased carotid IMT and carotid plaque presence, as summarized in the ASE Consensus Statement and other recent reviews. , In general, individuals with higher levels of carotid IMT have a 2- to 2.5-fold increased risk factor adjusted relative risk for incident CVD; those with plaque in general have a 2.5- to 3-fold increased risk. Representative studies that evaluated the associations of CVD risk with common carotid artery (CCA) IMT and carotid plaque presence in asymptomatic individuals are summarized in Tables 199.1 and 199.2 . The recent USE-IMT meta-analysis of 14 population-based cohorts and 45,828 individuals demonstrated that over a median of 11 years, the relative risk per 0.1-mm increase in CCA IMT was 1.08 (95% confidence interval [CI] 1.05 to 1.10) for myocardial infarction and 1.12 (95% CI 1.10 to 1.15) for stroke. Higher plaque burden also is predictive of increased CVD risk; its quantification is a promising advance in carotid ultrasound imaging for CVD risk prediction. ,
Study | N | Age | Years | Cardiovascular Disease Event | Cutpoint | Adjusted Relative Risk * (95% CI) |
---|---|---|---|---|---|---|
Atherosclerosis Risk in Communities | 12,841 | 45-64 | 5 | MI, CHD death | Tertile | Women: 2.53 (1.02-6.26) Men: 2.02 (1.32-3.09) |
14,214 | 45-64 | 7 | Stroke | Tertile | Women: 2.32 (1.09-4.94) Men: 2.24 (1.26-4.00) | |
Carotid Atherosclerosis Progression Study | 5056 | 19-90 | 4 | MI, stroke, death | Quartile | 1.85 (1.09-3.15) |
Cardiovascular Health Study | 4476 | > 65 | 6 | MI | Quintile | 3.61 (2.13-6.11) |
Stroke | Quintile | 2.57 (1.64-4.02) | ||||
Kuopio Ischemic Heart Disease | 1257 | 42-60 | 3 | MI | > 1.0 mm | 2.1 (0.8-5.2) |
Malmö Diet and Cancer Study | 5163 | 46-68 | 7 | MI, CHD death | Tertile | 1.50 (0.81-2.59) |
Multi-Ethnic Study of Atherosclerosis | 6698 | 45-84 | 4 | CHD, CHD death | Quartile | 2.3 (1.4-3.8) |
Rotterdam | 6389 | > 55 | 7-10 | MI | Quartile | 1.95 (1.19-3.19) |
San Danielle | 1348 | 18-99 | 12 | Stroke, transient ischemic attack, vascular death | > 1.0 mm | 5.6 (3.2-10.1) |
Tromso | 6226 | 25-84 | 5 | MI | Quartile | Women: 2.86 (1.07-7.65) Men: 1.73 (0.98-3.06) |
Yao City | 1289 | 60-74 | 5 | Stroke | Quartile | 4.9 (1.9-12.0) |